ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
Arch declined to comment on the new fundraising.
Science 37, one of the startups that fueled the rise in decentralized clinical trials, will go private and see its one-time $1 billion valuation evaporate
The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. What’s it like to work in an emergency department during
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) To survive, health tech startups got creative